The drug name of Margetuximab marketed in China

Margetuximab (Margetuximab) is an innovative targeted anti-cancer drug that belongs to the monoclonal antibody class. It is primarily used to treat patients with HER2-positive breast cancer, especially those who have developed resistance to standard anti-HER2 treatment regimens. Margetuximab inhibits the growth and spread of cancer cells by targeting the HER2 receptor and has been approved in many countries. However, despite the gradual launch of the drug in the global market, the original drug of margetuximab (trade name MARGENZA) is currently not officially launched in China, which means that patients are temporarily unable to directly purchase the drug in China.

Overseas, particularly in the United States, margituximab has been approved for use in combination with chemotherapy to treat patients with metastatic HER2-positive breast cancer. The drug has shown significant efficacy in these patients, especially for those who are resistant to traditional anti-HER2 drugs such as trastuzumab (Herceptin) and pertuzumab (Perjeta). Margetuximab provides a new treatment option.

For Chinese patients, the lack of direct marketing of margetuximab means they cannot obtain the drug in their local market. In China, there are relatively many options for breast cancer treatment, but for the treatment of HER2-positive breast cancer, especially when it is resistant to traditional drugs, patients' treatment options may be limited. Therefore, if patients wish to use margetuximab, they may need to import the drug or receive treatment overseas, which not only increases the financial burden but also restricts the availability of treatment.

With the increasing demand for breast cancer treatment and the successful application of margituximab in other countries, the drug is expected to obtain approval from the Chinese Food and Drug Administration and enter the domestic market in the future. Breast cancer patients in China will be able to benefit from the therapeutic effects of this innovative drug, thereby broadening their treatment options.

References: https://www.margenza.com/